#H.I.G. Capital #London #United Kingdom #Pharmaceutical Services #ITH Group

H.I.G. Capital Completes Acquisition of ITH Group Limited

On June 9, 2025, H.I.G. Capital, a prominent global alternative investment firm with $70 billion in capital under management, announced the successful completion of its acquisition of ITH Group Limited, a leading UK provider of aseptic pharmaceutical compounding services. This strategic move is in partnership with ITH's founders, Adam Bloom and Karen Hamling, who will continue to lead the company.

About ITH Group

Founded in 2008 and located in London, ITH Group specializes in providing customized injectable medications for patients with specific medical needs, particularly those not catered to by existing treatment options. Within the compounding services industry, ITH stands out as a market leader in areas such as chemotherapy, total parenteral nutrition, and central intravenous additives. The company also operates a leading digital pharmacy, catering to both private and NHS patients with essential, approved medications.

With a dedication to organic growth and new initiatives, H.I.G. aims to support ITH in expanding its production capacity while upholding the high standards the company has set.

Leadership Commitment

Adam Bloom, CEO of ITH Group, expressed enthusiasm about H.I.G.'s involvement as a key investor. He stated, “Since our inception, ITH has continuously grown by investing in our staff and improving patient services. We take pride in being a leading provider of compounding services, supporting both the NHS and private healthcare sectors.” He emphasized their future goals of expanding service offerings and deepening expertise in delivering vital, customized medications.

Karen Hamling, COO, noted the importance of maintaining a strong focus on high-quality customer service that built ITH's reputation as a reliable service provider.

H.I.G.’s managing director, John Harper, highlighted their excitement in assisting ITH in furthering its success. He stated, “ITH’s reliable delivery of tailored medications to NHS and private patients in an underserved market, combined with H.I.G.'s experience in supporting capacity expansions, lays a promising foundation for ITH’s next chapter.”

Looking Forward

Gordon Cameron, non-executive chairman of ITH, commended Bloom and Hamling for building an impressive business that serves a critical function within the UK healthcare system. With their commitment to high-quality customer service, ITH has earned a market-leading reputation for reliability. Cameron is eager to participate in H.I.G.'s investment journey to drive the next growth phase for the company.

H.I.G. Capital Overview

H.I.G. Capital is one of the world's leading alternative investment firms, involved in providing both debt and equity capital for mid-market businesses across various sectors. Since its inception in 1993, H.I.G. has invested in over 400 companies globally, managing a diverse portfolio that includes more than 100 companies with a combined revenue exceeding $53 billion. The firm's flexible and operationally focused approach is designed to create value and foster growth in its portfolio companies.

As H.I.G. integrates ITH Group into its portfolio, the firm is poised to leverage its resources to enhance the capabilities and reach of ITH, ensuring vital pharmaceutical services continue to flourish in the UK healthcare landscape.